# MedWellAI, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/MedWellAI, Inc.). ## Overview MedWellAI, Inc. is a Nevada-based holding company that has shifted from its earlier digital-asset/mining focus into AI-enabled healthcare and wellness businesses. Through subsidiaries such as MedWell USA and MedWell Facilities, it sells pharmaceutical products, supports provider ordering workflows, and pursues wellness-related real estate and service opportunities. ## Products & services • B2B e-commerce distribution of GLP medications • AI-powered ordering and inventory tracking platform • Provider support for clinics, med spas, and wellness facilities • Professional medical consultation coordination • Wellness-focused facilities and real estate development • Rental income from sub-leased properties - **Pharmaceutical product sales** (85%) — Bulk sale and distribution of GLP medications for weight loss and diabetes management. - **Commission and service revenue** (5%) — Commissions and service fees tied to customer transactions and consultation-enabled offerings. - **Online sales** (1%) — Legacy online sales activity that management has said it is no longer pursuing due to regulatory hurdles. - **Rental income** (4%) — Lease and sub-lease income from properties used in the wellness and healthcare ecosystem. - **Holding company and investment activities** (5%) — Corporate-level acquisition, investment, and development activities that support new business lines. - B2B e-commerce distribution of GLP medications - AI-powered ordering and inventory tracking platform - Provider support for clinics, med spas, and wellness facilities - Professional medical consultation coordination - Wellness-focused facilities and real estate development - Rental income from sub-leased properties ## Customers The company sells primarily to healthcare-related business customers rather than consumers, especially doctors’ offices, clinics, med spas, and corporate wellness facilities. It also works with affiliated medical groups and licensed providers to support consultation-enabled transactions, which makes the customer base dependent on both product demand and clinical workflow integration. - **Healthcare provider offices** (primary) — Doctors' offices and similar practices buy GLP medications and related services for patient use and recurring supply needs. - **Wellness clinics and med spas** (primary) — These customers use the platform to source products and streamline ordering for weight-loss and wellness programs. - **Corporate wellness facilities** (secondary) — Corporate wellness operators buy products and services to support employee wellness offerings. - **Affiliated medical groups and providers** (secondary) — Licensed providers deliver consultations that enable the company’s service revenue and prescription-related workflow. - Doctors' offices buying GLP medications for patient treatment programs - Clinics and med spas sourcing products through a B2B ordering platform - Corporate wellness facilities seeking provider-supported wellness offerings - Affiliated medical groups providing consultations tied to product sales - Single large customers can materially affect revenue due to concentration ## Geography MedWellAI is headquartered in the United States and its disclosed operations are centered in Nevada and Florida through its subsidiaries and acquired interests. The filings do not provide a meaningful country-by-country revenue split, but the business appears to be U.S.-focused and exposed to U.S. healthcare and pharmaceutical regulation. - Headquartered in the United States and incorporated in Nevada - Subsidiaries formed in Nevada to support new healthcare and wellness lines - Acquired Healthy Lifestyle USA LLC, a Florida-based business - Operations appear concentrated in the U.S. market - U.S. regulatory exposure is central to product and online sales strategy ## Strategy Management is repositioning the company around AI-driven healthcare and wellness after earlier digital-asset activities. Near-term priorities appear to be building the MedWell platform, expanding pharmaceutical distribution, and monetizing wellness-related facilities while avoiding business lines that face regulatory friction. - **Build the MedWell healthcare platform** (short-term) — The company needs a scalable operating base beyond legacy holdings and digital-asset activities. - **Expand provider-facing distribution relationships** (medium-term) — Revenue depends on repeat purchasing from clinics and offices that need reliable supply and support. - **Develop wellness facilities and real estate** (medium-term) — Facilities can create a broader ecosystem around healthcare customers and diversify revenue streams. - **Avoid regulatory-heavy online sales models** (short-term) — Management has already said it is no longer pursuing the online sales business due to regulatory hurdles. - Shift the company toward AI-enabled healthcare and wellness businesses - Scale B2B pharmaceutical distribution through MedWell USA - Use AI tools to improve ordering, inventory visibility, and provider support - Develop wellness-related facilities and real estate opportunities - Exit or de-emphasize online sales that face regulatory hurdles ## Risks The company remains early-stage, loss-making, and dependent on external financing, so execution risk is high. It also faces customer concentration, regulatory risk in healthcare/pharmaceutical distribution, and technology/compliance risk from using AI in a regulated environment. - **Customer concentration** [high] — One customer generated about 96% of revenue, so the loss of that customer would materially reduce sales. - **Going concern / financing risk** [critical] — The company has a history of losses and states it may need additional capital to continue operations. - **Regulatory risk in healthcare and online sales** [high] — Management discontinued online sales due to regulatory hurdles, showing the business model is sensitive to compliance constraints. - **AI and technology risk** [medium] — AI tools in healthcare can create privacy, bias, cybersecurity, and regulatory issues that may disrupt operations. - **Key-person dependence** [high] — The CEO is the sole officer and director, so loss of that person would impair management continuity. - High customer concentration can sharply reduce revenue if one buyer leaves - Going-concern uncertainty reflects losses and reliance on new financing - Healthcare and pharmaceutical regulation can limit product and online sales - AI use may create compliance, privacy, and fraud risks - Dependence on the CEO creates key-person risk ## Accounting Revenue recognition is judgmental because the company acts as principal for consultation-enabled services and recognizes product sales only when delivery occurs. Investors should also watch goodwill impairment, deferred revenue from prepaid product orders, and lease accounting for sub-leased properties, all of which can move reported earnings and balance-sheet values materially. - **Revenue recognition under ASC 606** — Can shift revenue between periods and affect reported margins - **Deferred revenue** — Affects working capital and near-term revenue timing - **Goodwill impairment** — Can create large non-cash charges and reduce equity - **Lease accounting** — Affects revenue timing and asset/liability presentation - **Stock-based compensation** — Can materially affect operating expenses and dilution - Principal-versus-agent judgment affects gross revenue presentation - Product sales are recognized on delivery, not at order placement - Prepayments create deferred revenue until products ship - Goodwill was fully impaired after the online sales business was abandoned - Sub-lease income is recognized under lease accounting over the lease term --- *Last updated: 2026-04-28T20:26:43.046781+00:00*